Treatment of Post-Punch Biopsy Bleeding in Apixaban-Treated Patients Using Self-Administered BXP154B

Inclusion Criteria: * Male or female ≥18 years of age on the day of signed informed consent. At least 8 subjects of each sex will be enrolled. * Currently receiving apixaban (Eliquis®) and on a BID dosing regimen 5 mg BID (10 mg total daily dose). Subjects must have been on the same dosing regimen for at least 7 days prior to Day 1. * Willing and able to provide informed consent prior to any study procedures and to comply with all aspects of the protocol Exclusion Criteria: * Allergy or sensitization to any components of BXP154B * BMI ≥ 50 kg/m2 * Known genetic/familial hypercoagulable disorder * Thrombocytopenia (platelets \<75,000/mm3) * Subjects using any prescribed chronic drug therapies that impact platelet function including clopidogrel (Plavix®), prasugrel (Effient®), ticagrelor (Brillinta®), dipyridamole (Aggrenox®), cilostazol (Pletal®), aspirin, or any non-steroidal anti-inflammatory drugs (NSAIDs; e.g., ibuprofen, naproxen, diclofenac, indomethacin, ketorolac, etc.) are excluded from participation in the study. NSAIDs or aspirin taken on an as needed (PRN) basis must be discontinued according to the following required windows prior to Day 1 (aspirin, 7 days; ibuprofen, 24 hours; all other NSAIDs, 4 days) and may not be taken for the duration of the study. * Use of any other anticoagulant therapies other than apixaban 5mg BID * Hypersensitivity to any local anesthetic being used by the site * Pregnant, breastfeeding, or planning to become pregnant * Use of any ho…